2-(3-aminophenyl)-N,N-diethylacetamide | 58730-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-aminophenyl)-N,N-diethylacetamide
• CAS: 58730-44-2
• 化学式: C₁₂H₁₈N₂O
• 分子量: 206.288
• InChiKey: HDUSIWCFLGALTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-aminophenyl)-N,N-diethylacetamide 、 I-podophyllotoxin 在 三乙胺 、 barium carbonate 作用下， 以 乙腈 为溶剂， 生成 4β-(N-[3-(2-oxo-2-(diethylamino)ethyl)phenyl]amino)-4'-O-demethyl-4-desoxypodophyllotoxin
  参考文献：
  名称：

  Synthesis and biological evaluation of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

  摘要：

  A series of new 4 beta-anilino-4'-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4 beta position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.016
• 作为产物：
  描述：

  N,N-二乙基-3-硝基苯乙酰胺 在 10% palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 生成 2-(3-aminophenyl)-N,N-diethylacetamide
  参考文献：
  名称：

  Synthesis and biological evaluation of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

  摘要：

  A series of new 4 beta-anilino-4'-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4 beta position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.016

文献信息

• US4067726A
  申请人：——

  公开号：US4067726A

  公开（公告）日：1978-01-10
• [EN] FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ HÉTÉROCYCLIQUE CONDENSÉ ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009119776A1

  公开（公告）日：2009-10-01

  　本発明は、強力なキナーゼ阻害活性を示す縮合複素環誘導体およびその用途を提供する。式 〔式中、各記号は明細書中と同意義である〕で表される化合物またはその塩、ならびに、キナーゼ阻害剤、癌の予防・治療剤である、当該化合物またはそのプロドラッグを含有してなる医薬。
• Synthesis and biological evaluation of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents
  作者：Li Wang、Fenyan Yang、Xiaochun Yang、Xianghong Guan、Chunqi Hu、Tao Liu、Qiaojun He、Bo Yang、Yongzhou Hu

  DOI：10.1016/j.ejmech.2010.11.016

  日期：2011.1

  A series of new 4 beta-anilino-4'-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4 beta position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route. (C) 2010 Elsevier Masson SAS. All rights reserved.